Preview: Kymera Therapeutics's Earnings
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) is set to release its quarterly earnings report on October 31, 2024. Analysts estimate an EPS of $-0.84. The company previously beat EPS estimates, leading to a share price increase. Analysts rate Kymera as 'Outperform' with a price target of $52.8, suggesting an 8.89% upside. Kymera's revenue growth is 55.33%, but it lags behind peers. The company has a strong net margin and ROE but a low ROA. Its debt-to-equity ratio is favorable.
October 30, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics is expected to report an EPS of $-0.84. The company has a history of beating estimates, which previously led to a share price increase. Analysts rate it 'Outperform' with a price target of $52.8, suggesting an 8.89% upside. The company's revenue growth is 55.33%, but it lags behind peers. It has a strong net margin and ROE, but a low ROA. Its debt-to-equity ratio is favorable.
Kymera Therapeutics is about to release its earnings report, and the market is anticipating the results. The company has a track record of beating EPS estimates, which has historically led to positive stock price movements. Analysts have a positive outlook on the stock, with an 'Outperform' rating and a price target suggesting an upside. The company's financial metrics, such as net margin and ROE, are strong, although it lags in revenue growth compared to peers. The favorable debt-to-equity ratio is a positive sign for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100